In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Veru Inc (VERU), with a price target of $4.50. The company’s shares closed yesterday at $1.97.
According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -27.5% and a 34.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aslan Pharmaceuticals Ltd, Seelos Therapeutics Inc, and Eyenovia Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru Inc with a $6.50 average price target.
See today’s analyst top recommended stocks >>
Based on Veru Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.03 million. In comparison, last year the company had a GAAP net loss of $3.83 million.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
